Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma

CONCLUSION LY3023414 monotherapy (200  mg BID) demonstrated an acceptable and manageable safety profile with limited single-agent activity in patients with advanced mesothelioma.ClinicalTrials.gov identifier: NCT01655225;Date of registration: 19 July 2012.

Source: Investigational New Drugs - March 4, 2021 Category: Drugs & Pharmacology Source Type: research